Edgewise Therapeutics (EWTX) Non-Current Assets (2020 - 2026)

Edgewise Therapeutics has disclosed Non-Current Assets across 7 years of filings, most recently posting $8.7 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $8.7 million, down 22.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $37.6 million (down 19.33% YoY), and the FY2025 annual result was $9.2 million, down 18.67% from the prior year.
• Non-Current Assets came in at $8.7 million for Q1 2026 at Edgewise Therapeutics, down from $9.2 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $13.6 million in Q2 2023 to a low of $4.1 million in Q2 2022.
• The 5-year median for Non-Current Assets is $11.2 million (2025), against an average of $10.3 million.
• Across the five-year window, Non-Current Assets surged 674.05% in 2022 and slipped 22.14% in 2026, its largest moves.
• Edgewise Therapeutics' Non-Current Assets stood at $10.1 million in 2022, then gained by 29.06% to $13.0 million in 2023, then declined by 13.07% to $11.3 million in 2024, then dropped by 18.67% to $9.2 million in 2025, then slipped by 5.29% to $8.7 million in 2026.
• The last three Non-Current Assets figures came in at $8.7 million (Q1 2026), $9.2 million (Q4 2025), and $9.6 million (Q3 2025), per Business Quant data.